Mary
Moderator Resource
- Messages
- 17,334
- Location
- Southern California
Okay, this study has to do with diabetes patients but it might have some relevance for ME/CFS:
http://www.ncbi.nlm.nih.gov/pubmed/21288652
It states in part:
http://www.ncbi.nlm.nih.gov/pubmed/21288652
It states in part:
Nitric oxide (NO) is synthesized by the endothelial cell and is also an important element for the viability and functionality of this cell type. However, in the DM patient, a deficient synthesis of NO has been reported. It is relevant to mention that recent evidences have led to propose mitochondrial activity as an important regulator of nitric oxide synthesis (ON). We consider that the exogenous administration of TPP facilitates the utilization of this molecule, regulating some metabolic processes such as phosphorylation of thiamine by TPPK, energy consumption (ATP), as well as mitochondrial activity, inducing eventually NO synthesis. If this is confirmed, the administration of TPP to the diabetic patient would provide additional protection to endothelial cells, reducing the risk of vascular damage, to which the diabetic patient is highly susceptible.